Join our daily newsletter At The Bell to receive exclusive market insights
With more than 600k average monthly users on the HotCopper forums, each and every discussion can move markets. That’s why getting in front of those red-hot trends is key for every trader worth their salt. In this daily HotCopper Trends column, we break down the top Oz stock movers through each trading day.
.png)
AVM | Gold project merger creates 2,000 sq km exploration portfolio
Advance Metals (ASX: AVM) was popular on HotCopper after it and Sky Metals (ASX: SKY) announced theyhad agreed to combine their respective Australian gold project interests into a new company.
The spin-out Newco will seek admission to the official list of the ASX.
The proposed spin-out would combine Advance’s Myrtleford and Beaufort hold projects in Victoria with SKY’s Cullarin, Kangiara and Caledonian projects in New South Wales.
The combined exploration portfolio will feature more than 2,000 sq, km across southeastern Australia.
NUZ | First HEALEY ALS trial participant enters active treatment extension
Neurizon Therapeutics (ASX: NUZ) has advised that the first participant in Regimen I of the phase 2/3 HEALEY ALS Platform trial has completed the 36-week placebo-controlled (RCT) phase and transitioned into the Active Treatment Extension (ATE).
The milestone marks the next stage in the progression of Regimen I, following the completion of enrolment of 250 participants in July 2026. As eligible participants reach Week 36, they may voluntarily continue into the extension, where all participants receive investigational NUZ-001 under the trial protocol.
The ATE is designed to generate additional longer-term safety, tolerability, functional and biomarker data, beyond the clinical evidence collected during the RCT phase. All participants entering the extension will receive NUZ-001, irrespective of their original treatment allocation.
Participants will continue to undergo regular clinical and safety assessments, including measures of functional decline using the ALS Functional Rating Scale-Revised (ALSFRS-R), respiratory function and quality of life. Blood and urine biomarker assessments, including neurofilament light chain (NfL), will also continue throughout the extension period. Treatment assignments remain blinded through the extension period.
INA | Warburg Pincus revises Ingenia takeover proposal, maintaining $5.55 offer
Ingenia Communities Group (ASX: INA) has received a further revised non-binding indicative proposal from Warburg Pincus LLC and others to acquire 100% of Ingenia’s stapled securities.
The updated proposal is by way of inter-conditional scheme of arrangement and trust schemes.
The WP non-exclusive proposal has not proposed any change in price to Warburg Pincus’ proposal announced on 6 November 2026, being $5.55 cash per stapled security plus any distribution paid by Ingenia for the half year ending 31 December 2026 of up to $0.05 per stapled security.
Ingenia said securityholders do not need to take any action in relation to the WP non-exclusive proposal or any proposal from AVID.
LOOKING WIDER | S&P/ASX 200 falls 0.66% as Lendlease and Smartgroup lead losses
Looking wider, the S&P/ASX 200 was lower today, dropping 60.20 points or 0.66% to 9,086.60. The bottom performing stocks in this index are Lendlase Group and Smartgroup Corporatoion, down 7.63% and 5.45% respectively. Over the last five days, the index has gained 0.73% and is currently 2.26% off of its 52-week high.
That’s Friday’s HotCopper Market Trends, I’m Colin Sandell-Hay - see you for close.
Join the discussion. See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
-1200x645-380x200.jpg)
-1200x645-380x200.jpg)